There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...

Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

Drug discovery for neurological disorders is undergoing a renaissance, with several ASX healthcare companies leading the ...

With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

NaturVet, a leader in pet health and wellness, will debut new product innovations and refreshed branding at Global Pet Expo from March 26-28 in Orlando, Florida. The brand's vet-formulated supplements ...

This award recognized LEQEMBI as “a world-first treatment for early AD developed in Japan which selectively binds to and clears neurotoxic substances (abnormal proteins), thereby reducing the rate of ...

AMBOSS, the leading resource for medical education and clinical decision-making in Germany and the US, closes a ?240M financing round with new long-term investors, supporting the exploration of ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi ...

In the first major deal at MIT’s ambitious overhaul of the old Volpe Center in Kendall Square, Cambridge drugmaker Biogen ...